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Letter to the editor
We read with interest Heise et al's case report and review
of the literature regarding the use of recombinant acti-
vated factor VII (rFVIIa) in patients with ventricular assist
devices (VAD) [1]. Whilst we welcome the addition to the
literature in this area, there are two key areas regarding
this relatively novel haemostatic agent that we felt the
authors had failed to address appropriately, and that may
therefore mislead the practicing cardiac surgeon.
RFVIIa's method of action; the source and role of 
tissue factor in cardiac surgery patients
In their discussion, the authors state that 'the effect of
rFVIIa on plasmatic coagulation derives from its interaction
with tissue factor. Thus, the pro-coagulatory effect is predomi-
nantly located in regions where tissues or vessels are injured'.
This is a simplification of a highly complex and only par-
tially understood process. The authors have based their
statement on what we know of endogenous Factor VIIa
and Tissue Factor (TF) interaction in physiological condi-
tions, where TF is present as an inactive pool on sub-
endothelial cells. Vessel injury exposes this TF to the
blood, where it binds and activates FVII. The resulting TF-
FVIIa complex catalyzes the conversion of factor X into its
active form (Xa), leading to thrombin formation and
platelet activation. This creates a surface that supports the
binding of coagulation factors and thereby facilitates the
full thrombin burst necessary for haemostasis.
One cannot presume that the pro-coagulatory effect of
rFVIIa occurs in the same way in patients undergoing VAD
surgery; significant controversy exists surrounding both
the source and the role of tissue factor in this setting. The
systemic inflammatory response witnessed in patients
undergoing major cardiac surgery involving artificial cir-
culatory support has a profound impact on the coagula-
tion system and thus TF expression is highly unlikely to be
restricted to the sub-endothelium. Several groups of inves-
tigators have reported the presence of physiologically
active 'blood-borne TF' in pro-inflammatory conditions,
including cardiac surgery [2-4]. What form this takes
remains unclear; blood-borne TF has been reported as
being located on blood cells, being an undefined mixture
of pro-coagulant micro-particles (0.1 to 1 μm) or being
soluble pro-coagulant TF fragments [5-7]. Pro-inflamma-
tory cytokines can stimulate neutrophils and monocytes
to produce and present TF on their surface [8,9] and
blood-borne TF in combination with activated monocytes
may activate FVII in cardiac surgical patients more than
when combined with activated platelets [2,10]. Further-
more, many patients undergoing VAD surgery suffer from
ischaemic cardiomyopathy. Within atherosclerotic
plaques, vascular smooth muscle cells, monocytes and
endothelial cells have all been reported to aberrantly
express and expose TF to the circulation [11]. Not only has
this been shown to be a critical event in atherothrombo-
sis, but this expression and exposition has been shown to
occur at higher levels in patients with symptomatic coro-
nary disease, suggesting a role for TF in plaque instability
[12].
The exact role of TF in rFVIIa's effect also requires further
elucidation. The high plasma concentrations of rFVIIa
required to induce haemostasis in refractory haemorrhage
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suggests that TF-dependent activation of the coagulation
cascade cannot be the sole mechanism of action. It has
been shown that rFVIIa is able to directly activate Factor X
on phospholipid vesicles, activated platelets and mono-
cytes, independently of TF [13-15], although TF-inde-
pendent generation of thrombin is much less efficient.
Whilst the authors alluded to TF-independent thrombin
generation in their introduction we feel this point must be
emphasised.
Patient safety – the risk of thromboembolic 
adverse events
We believe the authors have significantly underestimated
both the frequency and seriousness of the risk of throm-
boembolic (TE) complications in cardiac surgery patients.
They refer to 'the relatively low incidence of thromboembolic
events (1–2%) after the use of rFVIIa' in Levi et al's system-
atic review of the literature [16], but neglect to inform the
reader that over 50% of the data included in this synthesis
came from case reports or series. Furthermore less than
5% of the patients in this article were surgical patients, the
vast majority being haemophiliacs, in which rFVIIa is a
licensed treatment for haemorrhage. These are both cru-
cial factors, as they introduce a high risk of both publica-
tion and selection bias. Heise et al infer that because TE
complications in patients with VAD were not explicitly
mentioned in O'Connell et al's paper in 2006 [17] they
'seem to be very rare'. This conclusion simply cannot be
drawn from the available data. Whilst the authors refer to
this paper a second time, they fail to emphasise that
O'Connell et al stressed that most TE adverse events fol-
low the use of rFVIIa for unlabeled indications, and result
in serious morbidity and mortality.
It is difficult to know what the real risk of serious TE
adverse events in this cohort of patients is. In a systematic
data synthesis of the cardiac surgery literature performed
early this year, our group reported a TE adverse event rate
in adult patients treated for refractory haemorrhage of
5.3% [18]. This was very similar to the 6% quoted by Levy
et al who reviewed the critical safety data from 13 rFVIIa
clinical trials in patients with coagulopathy secondary to
anti-coagulation, cirrhosis, or severe traumatic injury
[19]. However, we would stress that even these studies are
likely to suffer from underreporting. Whatever the rate,
the morbidity and mortality of spontaneous arterial or
venous thrombosis are severe, and must not be under-
stated.
Conclusion
It is likely that the level and location of TF expression in
patients undergoing VAD surgery is significantly higher
and more widespread than in normal subjects, and thus
these patients are at risk of spontaneous intra-vascular
thrombosis if administered rFVIIa. The level of this risk is
currently unquantifiable. We agree wholeheartedly with
the authors' conclusion that rFVIIa is a promising thera-
peutic option when conventional treatments for refractory
haemorrhage have been exhausted, and use it in our own
clinical practice. However we wish to emphasise that care-
ful risk-benefit analysis must be made before prescribing
rFVIIa to any bleeding cardiac patient. Evidence-based rec-
ommendations regarding the use of rFVIIa in cardiac sur-
gery are available to the practicing cardiac surgeon or
anaesthetist and we refer our colleagues to these guide-
lines [20-22].
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